Advances in COVID-19-Related Myocarditis

A special issue of Biology (ISSN 2079-7737).

Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 5394

Special Issue Editor

1. Campus Virchow Klinikum (CVK), Berlin Institute of Health (BIH) Center for Regenerative Therapies (BCRT), Charité—Universitätsmedizin Berlin, 10017 Berlin, Germany
2. German Center for Cardiovascular Research (DZHK), Partner Site Berlin, 10017 Berlin, Germany
Interests: cardiology; immunology; animal models; disease modelling; functional left ventricular characterization; imaging; molecular investigations

Special Issue Information

Dear Colleagues,

In March 2020, the World Health Organization declared the coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to be a pandemic. Epidemiological data show that COVID-19 patients, who have concomitant established cardiovascular diseases are more likely to develop life-threatening complications from the infection. In turn, COVID-19 can lead to cardiovascular disease. Clinical manifestation of COVID-19-associated heart diseases includes the occurrence of impaired cardiac function, elevated troponin levels, arrhythmia, up to myocarditis. The underlying pathophysiology of COVID-19-associated heart diseases is diverse. It is suggested to be due to direct viral damage and myocardial injury mediated by cardiomyocyte apoptosis and disruption, myocardial interstitial fibrosis, endothelial inflammation, exaggerated cytokine response, and/or the host´s immune response. However, it is still not well understood.

This Special Issue will feature the latest scientific research in COVID-19-associated heart disease, including myocarditis. The vision of this Special Issue is to bring clinicians and basic scientists such as biologists, immunologists together, to update readers with the current knowledge of COVID-19-associated heart disease. Original research, review articles, case reports, communication and study protocols are welcome.

Dr. Kathleen Pappritz
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • viral myocarditis
  • COVID-19
  • cardiology
  • immunology

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

9 pages, 745 KiB  
Article
Long-Term Cardiovascular Outcome in Children with MIS-C Linked to SARS-CoV-2 Infection—An Italian Multicenter Experience
by Nicoletta Cantarutti, Virginia Battista, Nicola Stagnaro, Marianna Eleonora Labate, Marianna Cicenia, Marta Campisi, Valerio Vitali, Aurelio Secinaro, Andrea Campana, Gianluca Trocchio and Fabrizio Drago
Biology 2022, 11(10), 1474; https://0-doi-org.brum.beds.ac.uk/10.3390/biology11101474 - 08 Oct 2022
Cited by 7 | Viewed by 1658
Abstract
MIS-C is a multisystem inflammatory syndrome that is characterized by multi-organ failure and cardiac involvement. The aim of this study was to describe the long-term cardiovascular outcome in a cohort of MIS-C pediatric patients, who were admitted to two Italian Pediatric Referral Centers. [...] Read more.
MIS-C is a multisystem inflammatory syndrome that is characterized by multi-organ failure and cardiac involvement. The aim of this study was to describe the long-term cardiovascular outcome in a cohort of MIS-C pediatric patients, who were admitted to two Italian Pediatric Referral Centers. Sixty-seven patients (mean age 8.7 ± 4.7 years, male 60%) were included; 65 (97%) of them showed cardiac involvement. All of the patients completed one month of the follow-up, and 47% completed 1 year of it. ECG abnormalities were present in 65% of them, arrhythmias were present in 9% of them during an acute phase and it disappeared at the point of discharge or later. Pericarditis were detected in 66% of them and disappeared after 6 months. Coronaritis was observed in 35% of the children during an acute phase, and there were no more instances at the 1-year point. An LV dysfunction was present in 65% of the patients at the beginning of the study, with them having a full recovery at the point of discharge and thereafter. Elevated values of the NTproBNP and hsTp were initially detected, which progressively decreased and normalized at the points of discharge and FU. The CMR at the point of FU, there was a presence of long-term myocardial scars in 50% of the patients that were tested. No deaths that were caused by MIS-C during the FU were recorded. Cardiac involvement in MIS-C patients is almost the rule, but the patients’ clinical course was satisfactory, and no additional events or sequelae were observed apart from there being long-term myocardial scars in 50% of the patients that underwent CMR. Full article
(This article belongs to the Special Issue Advances in COVID-19-Related Myocarditis)
Show Figures

Figure 1

Review

Jump to: Research

16 pages, 794 KiB  
Review
COVID-19-Associated Myocarditis: An Evolving Concern in Cardiology and Beyond
by Meg Fraser, Arianne Clare C. Agdamag, Valmiki R. Maharaj, Melinda Mutschler, Victoria Charpentier, Mohammed Chowdhury and Tamas Alexy
Biology 2022, 11(4), 520; https://0-doi-org.brum.beds.ac.uk/10.3390/biology11040520 - 28 Mar 2022
Cited by 10 | Viewed by 3159
Abstract
The direct and indirect adverse effects of SARS-CoV-2 infection on the cardiovascular system, including myocarditis, are of paramount importance. These not only affect the disease course but also determine clinical outcomes and recovery. In this review, the authors aimed at providing an update [...] Read more.
The direct and indirect adverse effects of SARS-CoV-2 infection on the cardiovascular system, including myocarditis, are of paramount importance. These not only affect the disease course but also determine clinical outcomes and recovery. In this review, the authors aimed at providing an update on the incidence of Coronavirus disease-2019 (COVID-19)-associated myocarditis. Our knowledge and experience relevant to this area continues to evolve rapidly since the beginning of the pandemic. It is crucial for the scientific and medical community to stay abreast of current information. Contrasting early reports, recent data suggest that the overall incidence of SARS-CoV-2-associated myocarditis is relatively low, yet infected individuals are at a substantially increased risk. Therefore, understanding the pathophysiology and diagnostic evaluation, including the use of serum biomarkers and imaging modalities, remain important. This review aims to summarize the most recent data in these areas as they relate to COVID-19-associated myocarditis. Given its increasing relevance, a brief update is included on the proposed mechanisms of myocarditis in COVID-19 vaccine recipients. Full article
(This article belongs to the Special Issue Advances in COVID-19-Related Myocarditis)
Show Figures

Figure 1

Back to TopTop